{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:33:07Z","timestamp":1781796787931,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,7,6]],"date-time":"2013-07-06T00:00:00Z","timestamp":1373068800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Thyroid hormones have been shown to regulate breast cancer cells growth, the absence or reduction of thyroid hormones in cells could provoke a proliferation arrest in G0-G1 or weak mitochondrial activity, which makes cells insensitive to therapies for cancers through transforming into low metabolism status. This biological phenomenon may help explain why treatment efficacy and prognosis vary among breast cancer patients having hypothyroid, hyperthyroid and normal function. Nevertheless, the abnormal thyroid function in breast cancer patients has been considered being mainly caused by thyroid diseases, few studied influence of chemotherapy on thyroid function and whether its alteration during chemotherapy can influence the respose to chemotherapy is still unclear. So, we aimed to find the alterations of thyroid function and non-thyroidal illness syndrome (NTIS) prevalence druing chemotherapy in breast cancer patients, and investigate the influence of thyroid hormones on chemotherapeutic efficacy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Thyroid hormones and NTIS prevalence at initial diagnosis and during chemotherapy were analyzed in 685 breast diseases patients (369 breast cancer, 316 breast benign lesions). The influence of thyroid hormones on chemotherapeutic efficacy was evaluated by chemosensitization test, to compare chemotherapeutic efficacy between breast cancer cells with chemotherapeutics plus triiodothyronine (T<jats:sub>3<\/jats:sub>) and chemotherapeutics only.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In breast cancer, NTIS prevalence at the initial diagnosis was higher and increased during chemotherapy, but declined before the next chemotherapeutic course. Thyroid hormones decreased signigicantly during chemotherapy. T<jats:sub>3<\/jats:sub> can enhance the chemosensitivity of MCF-7 to 5-Fu and taxol, with progression from G0-G1 phase to S phase. The similar chemosensitization role of T<jats:sub>3<\/jats:sub> were found in MDA-MB-231. We compared chemotherapeutic efficacy among groups with different usage modes of T<jats:sub>3<\/jats:sub>, finding pretreatment with lower dose of T<jats:sub>3<\/jats:sub>, using higher dose of T<jats:sub>3<\/jats:sub> together with 5-Fu or during chemotherapy with 5-Fu were all available to achieve chemosensitization, but pretreatment with lower dose of T<jats:sub>3<\/jats:sub> until the end of chemotherapy may be a safer and more efficient therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Taken together, thyroid hormones decreasing during chemotherapy was found in lots of breast cancer patients. On the other hand, thyroid hormones can enhance the chemotherapeutic efficacy through gatherring tumor cells in actively proliferating stage, which may provide a new adjuvant therapy for breast cancer in furture, especially for those have hypothyroidism during chemotherapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-13-334","type":"journal-article","created":{"date-parts":[[2013,7,6]],"date-time":"2013-07-06T18:14:12Z","timestamp":1373134452000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Implication from thyroid function decreasing during chemotherapy in breast cancer patients: chemosensitization role of triiodothyronine"],"prefix":"10.1186","volume":"13","author":[{"given":"Jianbo","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangbin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaobo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kainan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guosheng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingquan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,6]]},"reference":[{"issue":"5","key":"4013_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2265.2007.02813.x","volume":"66","author":"M Paulides","year":"2007","unstructured":"Paulides M, Dorr HG, Stohr W, Bielack S, Koscielniak E, Klingebiel T, Jurgens H, Bolling T, Willich N, Sauer R, et al: Thyroid function in paediatric and young adult patients after sarcoma therapy: a report from the Late Effects Surveillance System. Clin Endocrinol (Oxf). 2007, 66 (5): 727-731. 10.1111\/j.1365-2265.2007.02813.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"4013_CR2","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0022-3476(05)80288-4","volume":"119","author":"AL Ogilvy-Stuart","year":"1991","unstructured":"Ogilvy-Stuart AL, Shalet SM, Gattamaneni HR: Thyroid function after treatment of brain tumors in children. J Pediatr. 1991, 119 (5): 733-737. 10.1016\/S0022-3476(05)80288-4.","journal-title":"J Pediatr"},{"issue":"3","key":"4013_CR3","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1365-2265.1982.tb00720.x","volume":"16","author":"PH Willemse","year":"1982","unstructured":"Willemse PH, Sleijfer DT, Sluiter WJ, Koops HS, Doorenbos H: Alterations in thyroid hormone metabolism during chemotherapy in patients with testicular carcinoma. Clin Endocrinol (Oxf). 1982, 16 (3): 303-313. 10.1111\/j.1365-2265.1982.tb00720.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"4013_CR4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1447-0756.2008.00770.x","volume":"34","author":"TY Hsieh","year":"2008","unstructured":"Hsieh TY, Hsu KF, Kuo PL, Huang SC: Uterine choriocarcinoma accompanied by an extremely high human chorionic gonadotropin level and thyrotoxicosis. J Obstet Gynaecol Res. 2008, 34 (2): 274-278. 10.1111\/j.1447-0756.2008.00770.x.","journal-title":"J Obstet Gynaecol Res"},{"issue":"2","key":"4013_CR5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1590\/S0004-27302005000200022","volume":"49","author":"LH Meister","year":"2005","unstructured":"Meister LH, Hauck PR, Graf H, Carvalho GA: Hyperthyroidism due to secretion of human chorionic gonadotropin in a patient with metastatic choriocarcinoma. Arq Bras Endocrinol Metabol. 2005, 49 (2): 319-322.","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"9382","key":"4013_CR6","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0140-6736(03)14073-1","volume":"362","author":"DS Cooper","year":"2003","unstructured":"Cooper DS: Hyperthyroidism. Lancet. 2003, 362 (9382): 459-468. 10.1016\/S0140-6736(03)14073-1.","journal-title":"Lancet"},{"issue":"5","key":"4013_CR7","first-page":"397","volume":"58","author":"A Majkowska-Mlynarczyk","year":"2007","unstructured":"Majkowska-Mlynarczyk A, Kinalski M, Zaczek-Kucharska E: The thyroid gland function assessment in women after mastectomy and chemotherapy during breast cancer therapy. Endokrynol Pol. 2007, 58 (5): 397-402.","journal-title":"Endokrynol Pol"},{"issue":"2","key":"4013_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1023\/B:BREA.0000010708.99455.e1","volume":"83","author":"N Kumar","year":"2004","unstructured":"Kumar N, Allen KA, Riccardi D, Bercu BB, Cantor A, Minton S, Balducci L, Jacobsen PB: Fatigue, weight gain, lethargy and amenorrhea in breast cancer patients on chemotherapy: is subclinical hypothyroidism the culprit?. Breast Cancer Res Treat. 2004, 83 (2): 149-159. 10.1023\/B:BREA.0000010708.99455.e1.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"4013_CR9","doi-asserted-by":"publisher","first-page":"646","DOI":"10.2460\/ajvr.2000.61.646","volume":"61","author":"MG Conzemius","year":"2000","unstructured":"Conzemius MG, Graham JC, Haynes JS, Graham CA: Effects of treatment with growth hormone and somatostatin on efficacy of diammine [1,1-cyclobutane dicarboxylato (2-)-0,0']-(SP-4-2) in athymic rats with osteosarcoma. Am J Vet Res. 2000, 61 (6): 646-650. 10.2460\/ajvr.2000.61.646.","journal-title":"Am J Vet Res"},{"issue":"12","key":"4013_CR10","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.1158\/0008-5472.CAN-08-3694","volume":"69","author":"Y Wang","year":"2009","unstructured":"Wang Y, Li J, Cui Y, Li T, Ng KM, Geng H, Li H, Shu XS, Liu W, Luo B, et al: CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res. 2009, 69 (12): 5194-5201. 10.1158\/0008-5472.CAN-08-3694.","journal-title":"Cancer Res"},{"issue":"11","key":"4013_CR11","doi-asserted-by":"publisher","first-page":"5267","DOI":"10.1210\/endo.140.11.7145","volume":"140","author":"G Barrera-Hernandez","year":"1999","unstructured":"Barrera-Hernandez G, Park KS, Dace A, Zhan Q, Cheng SY: Thyroid hormone-induced cell proliferation in GC cells is mediated by changes in G1 cyclin\/cyclin-dependent kinase levels and activity. Endocrinology. 1999, 140 (11): 5267-5274. 10.1210\/en.140.11.5267.","journal-title":"Endocrinology"},{"issue":"1","key":"4013_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.bbrc.2011.09.024","volume":"414","author":"S Suhane","year":"2011","unstructured":"Suhane S, Ramanujan VK: Thyroid hormone differentially modulates Warburg phenotype in breast cancer cells. Biochem Biophys Res Commun. 2011, 414 (1): 73-78. 10.1016\/j.bbrc.2011.09.024.","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"4013_CR13","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/BF03349151","volume":"26","author":"LJ DeGroot","year":"2003","unstructured":"DeGroot LJ: \"Non-thyroidal illness syndrome\" is functional central hypothyroidism, and if severe, hormone replacement is appropriate in light of present knowledge. J Endocrinol Invest. 2003, 26 (12): 1163-1170.","journal-title":"J Endocrinol Invest"},{"issue":"25","key":"4013_CR14","first-page":"1414","volume":"299","author":"S Rubenfeld","year":"1978","unstructured":"Rubenfeld S: Euthyroid sick syndrome. N Engl J Med. 1978, 299 (25): 1414-","journal-title":"N Engl J Med"},{"issue":"1","key":"4013_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1365-2265.1978.tb03569.x","volume":"9","author":"MH Jonckheer","year":"1978","unstructured":"Jonckheer MH, Blockx P, Broeckaert I, Cornette C, Beckers C: 'Low T3 syndrome' in patients chronically treated with an iodine-containing drug, amiodarone. Clin Endocrinol (Oxf). 1978, 9 (1): 27-35. 10.1111\/j.1365-2265.1978.tb03569.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"4013_CR16","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1210\/endo-79-5-964","volume":"79","author":"VA Galton","year":"1966","unstructured":"Galton VA, Ingbar SH: Effect of a malignant tumor on thyroxine metabolism and thyroid function in the rat. Endocrinology. 1966, 79 (5): 964-970. 10.1210\/endo-79-5-964.","journal-title":"Endocrinology"},{"issue":"3","key":"4013_CR17","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1089\/thy.1991.1.235","volume":"1","author":"M Poth","year":"1991","unstructured":"Poth M, Tseng YC, Wartofsky L: Inhibition of TSH activation of human cultured thyroid cells by tumor necrosis factor: an explanation for decreased thyroid function in systemic illness?. Thyroid. 1991, 1 (3): 235-240. 10.1089\/thy.1991.1.235.","journal-title":"Thyroid"},{"issue":"4","key":"4013_CR18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1089\/thy.1993.3.325","volume":"3","author":"XP Pang","year":"1993","unstructured":"Pang XP, Yoshimura M, Hershman JM: Suppression of rat thyrotroph and thyroid cell function by tumor necrosis factor-alpha. Thyroid. 1993, 3 (4): 325-330. 10.1089\/thy.1993.3.325.","journal-title":"Thyroid"},{"issue":"2","key":"4013_CR19","first-page":"215","volume":"28","author":"H Nellen Hummel","year":"1997","unstructured":"Nellen Hummel H, Gutierrez Espindola G, Talavera J, Gordon F, Halabe J, Flores G: Effect of chemotherapy on thyroid hormone concentration in patients with malignant hematologic diseases. Arch Med Res. 1997, 28 (2): 215-217.","journal-title":"Arch Med Res"},{"issue":"3","key":"4013_CR20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/BF02774261","volume":"22","author":"T Kano","year":"1987","unstructured":"Kano T, Kojima T, Takahashi T, Muto Y: Serum thyroid hormone levels in patients with fulminant hepatitis: usefulness of rT3 and the rT3\/T3 ratio as prognostic indices. Gastroenterol Jpn. 1987, 22 (3): 344-353.","journal-title":"Gastroenterol Jpn"},{"issue":"11","key":"4013_CR21","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1089\/thy.2005.15.1253","volume":"15","author":"JL Kuijpens","year":"2005","unstructured":"Kuijpens JL, Nyklictek I, Louwman MW, Weetman TA, Pop VJ, Coebergh JW: Hypothyroidism might be related to breast cancer in post-menopausal women. Thyroid. 2005, 15 (11): 1253-1259. 10.1089\/thy.2005.15.1253.","journal-title":"Thyroid"},{"issue":"4A","key":"4013_CR22","first-page":"2069","volume":"16","author":"T Yokoe","year":"1996","unstructured":"Yokoe T, Iino Y, Takei H, Horiguchi J, Koibuchi Y, Maemura M, Ohwada S, Morishita Y: Relationship between thyroid-pituitary function and response to therapy in patients with recurrent breast cancer. Anticancer Res. 1996, 16 (4A): 2069-2072.","journal-title":"Anticancer Res"},{"issue":"1","key":"4013_CR23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/annonc\/mdp265","volume":"21","author":"SF Oosting","year":"2010","unstructured":"Oosting SF, de Haas EC, Links TP, de Bruin D, Sluiter WJ, de Jong IJ, Hoekstra HJ, Sleijfer DT, Gietema JA: Prevalence of paraneoplastic hyperthyroidism in patients with metastatic non-seminomatous germ-cell tumors. Ann Oncol. 2010, 21 (1): 104-108. 10.1093\/annonc\/mdp265.","journal-title":"Ann Oncol"},{"issue":"2","key":"4013_CR24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.beem.2004.03.010","volume":"18","author":"JM Hershman","year":"2004","unstructured":"Hershman JM: Physiological and pathological aspects of the effect of human chorionic gonadotropin on the thyroid. Best Pract Res Clin Endocrinol Metab. 2004, 18 (2): 249-265. 10.1016\/j.beem.2004.03.010.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"5","key":"4013_CR25","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1089\/thy.1995.5.425","volume":"5","author":"M Yoshimura","year":"1995","unstructured":"Yoshimura M, Hershman JM: Thyrotropic action of human chorionic gonadotropin. Thyroid. 1995, 5 (5): 425-434. 10.1089\/thy.1995.5.425.","journal-title":"Thyroid"},{"issue":"12","key":"4013_CR26","first-page":"913","volume":"47","author":"JM Hershman","year":"1972","unstructured":"Hershman JM: Hyperthyroidism induced by trophoblastic thyrotropin. Mayo Clin Proc. 1972, 47 (12): 913-918.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"4013_CR27","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1210\/jc.78.4.862","volume":"78","author":"M Yoshimura","year":"1994","unstructured":"Yoshimura M, Pekary AE, Pang XP, Berg L, Goodwin TM, Hershman JM: Thyrotropic activity of basic isoelectric forms of human chorionic gonadotropin extracted from hydatidiform mole tissues. J Clin Endocrinol Metab. 1994, 78 (4): 862-866. 10.1210\/jc.78.4.862.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"4013_CR28","doi-asserted-by":"publisher","first-page":"307","DOI":"10.7326\/0003-4819-83-3-307","volume":"83","author":"HP Higgins","year":"1975","unstructured":"Higgins HP, Hershman JM, Kenimer JG, Patillo RA, Bayley TA, Walfish P: The thyrotoxicosis of hydatidiform mole. Ann Intern Med. 1975, 83 (3): 307-311. 10.7326\/0003-4819-83-3-307.","journal-title":"Ann Intern Med"},{"issue":"1","key":"4013_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0305-7372(97)90017-7","volume":"23","author":"PM Fisher","year":"1997","unstructured":"Fisher PM, Hancock BW: Gestational trophoblastic diseases and their treatment. Cancer Treat Rev. 1997, 23 (1): 1-16. 10.1016\/S0305-7372(97)90017-7.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"4013_CR30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0002-9343(88)80351-6","volume":"85","author":"R Rajatanavin","year":"1988","unstructured":"Rajatanavin R, Chailurkit LO, Srisupandit S, Tungtrakul S, Bunyaratvej S: Trophoblastic hyperthyroidism: clinical and biochemical features of five cases. Am J Med. 1988, 85 (2): 237-241. 10.1016\/S0002-9343(88)80351-6.","journal-title":"Am J Med"},{"issue":"9","key":"4013_CR31","first-page":"3515","volume":"39","author":"MS Kumar","year":"1979","unstructured":"Kumar MS, Chiang T, Deodhar SD: Enhancing effect of thyroxine on tumor growth and metastases in syngeneic mouse tumor systems. Cancer Res. 1979, 39 (9): 3515-3518.","journal-title":"Cancer Res"},{"issue":"6","key":"4013_CR32","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/cncr.20881","volume":"103","author":"M Cristofanilli","year":"2005","unstructured":"Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, Hsu L, Krishnamurthy S, Theriault RL, Hortobagyi GN: Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer. 2005, 103 (6): 1122-1128. 10.1002\/cncr.20881.","journal-title":"Cancer"},{"issue":"1B","key":"4013_CR33","first-page":"617","volume":"23","author":"AA Hercbergs","year":"2003","unstructured":"Hercbergs AA, Goyal LK, Suh JH, Lee S, Reddy CA, Cohen BH, Stevens GH, Reddy SK, Peereboom DM, Elson PJ, et al: Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I\/II study. Anticancer Res. 2003, 23 (1B): 617-626.","journal-title":"Anticancer Res"},{"key":"4013_CR34","first-page":"1889","volume-title":"Cancer Medicine, Volume 2","author":"GM Richard","year":"2003","unstructured":"Richard GM, Gabriel NH, Thomas A: Neoplasms of the Breast. Cancer Medicine, Volume 2. Edited by: Donald WK, Raphaele P, Ralphr W, Robert CB, Ted SG, James FH, Emil F. 2003, Frei: BC Decker, 1889-6","edition":"6"},{"issue":"10","key":"4013_CR35","first-page":"3825","volume":"29","author":"M Yalcin","year":"2009","unstructured":"Yalcin M, Bharali DJ, Lansing L, Dyskin E, Mousa SS, Hercbergs A, Davis FB, Davis PJ, Mousa SA: Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts. Anticancer Res. 2009, 29 (10): 3825-3831.","journal-title":"Anticancer Res"},{"issue":"54","key":"4013_CR36","doi-asserted-by":"publisher","first-page":"8756","DOI":"10.1038\/sj.onc.1208126","volume":"23","author":"E Porlan","year":"2004","unstructured":"Porlan E, Vega S, Iglesias T, Rodriguez-Pena A: Unliganded thyroid hormone receptor beta1 inhibits proliferation of murine fibroblasts by delaying the onset of the G1 cell-cycle signals. Oncogene. 2004, 23 (54): 8756-8765. 10.1038\/sj.onc.1208126.","journal-title":"Oncogene"},{"issue":"7","key":"4013_CR37","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1590\/S0004-27302009000700010","volume":"53","author":"SH Cestari","year":"2009","unstructured":"Cestari SH, Figueiredo NB, Conde SJ, Clara S, Katayama ML, Padovani CR, Brentani MM, Nogueira CR: Influence of estradiol and triiodothyronine on breast cancer cell lines proliferation and expression of estrogen and thyroid hormone receptors. Arq Bras Endocrinol Metabol. 2009, 53 (7): 859-864. 10.1590\/S0004-27302009000700010.","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"5","key":"4013_CR38","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/sj.onc.1205136","volume":"21","author":"S Dinda","year":"2002","unstructured":"Dinda S, Sanchez A, Moudgil V: Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. Oncogene. 2002, 21 (5): 761-768. 10.1038\/sj.onc.1205136.","journal-title":"Oncogene"},{"issue":"6","key":"4013_CR39","doi-asserted-by":"publisher","first-page":"E1238","DOI":"10.1152\/ajpendo.00480.2009","volume":"297","author":"PJ Davis","year":"2009","unstructured":"Davis PJ, Davis FB, Lin HY, Mousa SA, Zhou M, Luidens MK: Translational implications of nongenomic actions of thyroid hormone initiated at its integrin receptor. Am J Physiol Endocrinol Metab. 2009, 297 (6): E1238-1246. 10.1152\/ajpendo.00480.2009.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"4013_CR40","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.mehy.2012.12.037","volume":"80","author":"J Huang","year":"2013","unstructured":"Huang J, Ji G, Xing L, Li H, Wang Z, Ren G, Wu K, Kong L: Neo-endocrinochemotherapy: a novel approach for enhancing chemotherapeutic efficacy in clinic?. Med Hypotheses. 2013, 80 (4): 441-446. 10.1016\/j.mehy.2012.12.037.","journal-title":"Med Hypotheses"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-334.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-13-334\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-334","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-334.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T01:07:36Z","timestamp":1630544856000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-13-334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,6]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["4013"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-13-334","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,6]]},"assertion":[{"value":"4 October 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"334"}}